Shareholders accepted all motions at the 2019 AGM

Newron announces 2018 financial results and provides outlook for 2019

Newron Supports Global Rare Disease Day® 2019

Newron to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Newron Completes Patient Enrollment in Pivotal STARS Study

Newron Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference in New York

Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for PD in Canada

Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease

Newron Pharmaceuticals hosts its 2018 R&D Day in New York City

Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m

Pagination